Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Alopecia totalis/universalis involves more intense immune activity and inflammation than patchy alopecia areata.

This study identified key proteins, FKBP10 and FBN2, that promote the growth cycle of secondary hair follicles in cashmere goats, with higher expression in the anagen phase, offering insights into mechanisms potentially enhancing cashmere yield and quality.

This case study reports that tofacitinib effectively treated alopecia areata in a patient with Crohn's disease and maintained her Crohn's disease management.

Certain hairstyles can cause scalp diseases, smoking is linked to hair loss, 5% minoxidil foam is effective for hair loss treatment, and various factors influence wound healing and hair growth.

EGF and TGF-α help maintain hair cell cultures, but TGF-β1 stops their growth.

In this study, only 1 out of 5 patients with anti-TNF-α induced psoriasiform eruptions showed good response to topical treatment, while systemic therapy and discontinuation of anti-TNF-α may prevent scarring alopecia in severe cases.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

The researchers reported that oral finasteride 1 mg was associated with more frequent reports of sexual adverse events than dutasteride 0.5 mg, particularly after 2012, which may be influenced by the nocebo effect.

This study analyzed reports from the FDA Adverse Event Reporting System and observed an upward trend in suicidality-related safety signals among young male finasteride users since 2019, peaking in 2022, highlighting emerging psychiatric safety concerns and the need for vigilant monitoring of this population.

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

This study found that the 1 mg dose of finasteride was associated with a wide range of adverse effects, including sexual, psychological, and metabolic symptoms, in the FAERS data.

This study found that finasteride 1 mg daily significantly increased hair density and improved appearance in men with androgenetic alopecia, with 66% showing visibly thicker hair after two years compared to 7% in the placebo group.

This case report suggests that starting selective Janus kinase 1 inhibition may improve alopecia in a patient with rheumatoid arthritis who was not responding to TNF-α inhibitor therapy and corticosteroids.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This study found that finasteride at a low dose of 0.1 mg/kg significantly reduced prostate size in male dogs with benign prostatic hyperplasia without causing toxic side effects.

This article discusses androgenetic alopecia in men and reports that finasteride at 1 mg/day for 24 months is generally well tolerated and may effectively inhibit hair loss.

Dermatologists should consider alpha-gal syndrome in patients with unexplained chronic skin issues.

This study reports the crystal structure and geometric parameters of a modified Finasteride derivative, highlighting significant differences in dihedral angles compared to its solvated analog and computational models.

This study explored the in vitro skin penetration of two compounds from Tectona grandis leaf extract used for standardization and found that compound 1 penetrates more efficiently than compound 2, especially with a propylene glycol enhancer.

This study found that sex differences in somatostatin biosynthesis in rat hypothalamic neurons develop between postnatal day 1 and 5, influenced by the conversion of testosterone to estrogen.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

This abstract indicates that finasteride, at a dose of 1 mg per day, is effective in treating androgenetic alopecia in men by significantly reducing DHT levels.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

Some patients lost hair after taking interferon alpha 2B, but it improved for some while still on the treatment and for others after stopping it.

This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.

Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.

In this study, researchers found that using a 5-α reductase inhibitor may reduce inflammation-related cytokines associated with T-helper cell 1 and T-helper cell 2 in prostate tissues after surgery, but it did not affect those related to Th17 cells.